Lemzoparlimab is a monoclonal antibody commercialized by I-Mab, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According to Globaldata, it is involved in 10 clinical trials, of which 3 were completed, 1 is ongoing, 4 are planned, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Lemzoparlimab’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Lemzoparlimab is expected to reach an annual total of $193 mn by 2036 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
TJC-4 (lemzoparlimab) is under development for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), diffuse large B-cell lymphoma or indolent B-cell lymphoma, relapsed or refractory acute myeloid leukemia, myelodysplastic syndrome, primary mediastinal b-cell lymphoma, non-small-cell lung carcinoma (NSCLC), epithelial ovarian cancer, fallopian tube and primary peritoneal cancer and for solid tumor. The drug candidate is developed based on hybridoma and phage display technologies. It acts by targeting CD47. It is administered through intravenous route. It was also under development for the treatment of non-Hodgkin's lymphoma, urothelial (bladder) cancer.
It was also under development for the treatment of melanoma, gastric cancer, head and neck squamous cell carcinoma, relapsed and refractory and newly diagnosed multiple myeloma,
I-Mab is a biopharmaceutical company. It develops transformational medicines for therapeutic areas of immuno-oncology and autoimmune diseases. Its pipeline product portfolio comprises TJ202, a CD38 antibody for treating multiple myeloma; TJ101, a recombinant human growth hormone (rhGH) used in pediatric patients with growth hormone deficiency; TJ301, an IL-6 inhibitor for ulcerative colitis; enoblituzumab, a B7-H3 antibody against tumors; and TJ107, an oncology care agent to treat cancer treatment-related lymphopenia. I-Mab utilizes various molecular engineering platforms to develop drug molecules with defined biological properties. The company collaborates with biotechnology companies, CROs, and CMOs to advance the clinical development of its pipeline assets and out-licensing opportunities. It operates in China, Hong Kong and the US. I-Mab is headquartered in Shanghai, China.
The company reported revenues of (Renminbi) CNY221.6 million for the fiscal year ended December 2022 (FY2022), compared to a revenue of CNY88 million in FY2021. The operating loss of the company was CNY1,969.5 million in FY2022, compared to an operating loss of CNY2,071.3 million in FY2021. The net loss of the company was CNY2,507.3 million in FY2022, compared to a net loss of CNY2,331.5 million in FY2021.
For a complete picture of Lemzoparlimab’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.